Histone lysine methyltransferases (KMT) and demethylases (KDM) underpin generegulation. Here we demonstrate that variants causing haploinsufficiency of KMTs and KDMs are frequently encountered in individuals with developmental disorders. Using a combination of human variation databases and existing animal models we determine 22
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Post-translational methylation and demethylation of lysine residues on histone tails is a key dynamic chromatin modification that is mediated by specific methyltransferases (KMTs) and demethylases (KDMs) and underpins gene regulation and several cellular processes 1; 2 .
Twenty-seven KMT and 24 KDM encoding genes, classified into eight groups each, are known (Table S1 ) 3 . Of these, heterozygous variants in seven KMT and four KDM genes are associated with autosomal and X-linked dominant inherited human developmental disorders (DDs) in the Online Mendelian Inheritance in Man database (OMIM) ( Table S1 ) [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .
We reviewed published disease-causing variants in KMTs and KDMs in the Human Gene
Mutation Database 19 and deduced that ~75% of these were predicted to be heterozygous protein truncating variants (PTVs), suggesting that haploinsufficiency is the predominant mechanism for the associated diseases ( Figure 1A ) (Table S2 ). This is consistent with previous studies that have shown a high prevalence of de novo (DN) PTVs in dominant DDs [20] [21] [22] . We reviewed phenotypes of the available mouse models for KMT and KDM orthologs (Table S1 ) 23 and found that heterozygous mouse models for six of the 11 known dominant DD-associated KMTs/KDMs and 12 of the 40 of remaining KMTs/KDMs demonstrate anomalies. We reviewed phenotypes of the available zebrafish knockdown (KD) models for KMT and KDM orthologs (Table S1 ) 24 . Anomalies were observed in KD of seven of the 11 known dominant DD-associated KMTs/KDMs and 18 of the 40 of remaining KMTs/KDMs. The human mutational landscape of KMTs/KDMs and the information from animal models led us to hypothesize that germline heterozygous PTVs in additional KMTs/KDMs may underlie as yet unknown DDs.
For each of the 51 KMTs/KDMs, we compiled selected indices of predicted intolerance to loss of function (LoF) pathogenic variants (Table S1 ). The pLI (probability of being LoF Intolerant) scores obtained from ExAC Browser 25 were found to be within a narrow range of 0.99-1.0 for KMTs and KDMs already linked with dominant human DDs suggesting a high reliability. The ranges of Residual Variation Intolerance score (0.06-51.92) and
Haploinsufficiency Index (3.06-62.96) scores for these genes were broad 26; 27 . We used a pLI score 25 cut-off of >0.9 to determine additional 11 KMTs and 11 KDMs as candidates for as yet unknown dominant human DDs ( Figure 1B ).
We examined the data from 4,293 trios who underwent exome sequencing as part of the Deciphering Developmental Disorders (DDD) study 22 . All these procedures were in accordance with the ethical standards (Multi-Centre Research Ethics Committee approval 10/H0305/83 and GEN/284/12) and informed consent was obtained from all the participants.
The previously described pipeline was used to identify rare high-quality and possibly deleterious variants in our list of 51 KMTs/KDMs. Rare variants were defined as those with minor allele frequencies of <0.001 (for de novo, X-linked and dominant heterozygous inheritances) or <0.01 (for compound heterozygous, recessive homozygous) in the Exome Aggregation Consortium 25 (ExAC, Version 0.3.1), the 1000 Genomes Project (1K-G) 28 , 6 of the canonical transcripts of these 11 genes is ~0.3% out of the total human exome size (0.092/30 Mb) 31 ( Figure 1C ). Hence, this is an important group of genes in rare undiagnosed developmental disorders. Fifty-two out of these 218 affected individuals had likely benign variants or variants of uncertain significance in these 11 KMTs/KDMs ( Figure 1C ) (Table   S4 ).
22; 31-33
One hundred and two of 218 probands had 120 rare high-quality call genetic variants in KMTs/KDMs not yet firmly associated with DDs (Table S5 ). Of these, 83 variants were in our 22 candidates for dominant DDs, including 9 PTVs and 16 DN protein-altering variants (PAV) ( Table S5) . Chi-square test revealed a 1.87-fold enrichment (95% Confidence Interval
[CI]=0.93-3.76; p=0.072) in the frequency of PTVs in these 22 genes in our cohort against the data from ExAC 25 (Table S6) . Similarly, a 4.85-fold enrichment of DN PAVs (95%CI=1.78-13.26; p =0.00065) was observed in these 22 genes in our cohort against the entries marked as 'controls' in "denovo-db" 34 (Table S6 ).This observation supported our hypothesis that germline heterozygous PTVs in additional KMTs/KDMs may underlie as yet unknown dominant DDs.
We then focused on DN PTVs in our curated list of candidates KMT for dominant DD because these variants are highly likely to be causal (equivalent to category 1 in the American 606834) (Figure 2 Figure 3 ).
Importantly, in contrast with the previously described individuals, this girl did not show any evidence of dystonia by the age of 11 years, even with careful reverse phenotyping 61 .
Interestingly, some of the previously reported individuals had normal development 59; 60 . Our findings broaden the phenotype of KMT2B variants and show that any combination of developmental delay and dystonia can result from heterozygous PTVs in this gene. KMT2B is highly expressed in both embryonic and adult human brains 50; 51 . In adults, it is specifically high-expressed in pituitary, cerebellum and bladder 50 . Of note, the affected individual that we describe has growth hormone deficiency, abnormal gait, nystagmus and urinary incontinence.
The Kmt2b KO mice die before stage E11.5 and display growth retardation, neural tube defects, pericardial effusion, abnormal heart looping, and head abnormalities, whereas the heterozygous mice exhibit fasting hyperinsulinemia, glucose intolerance and fatty liver disease 62; 63 .
Next, we systematically explored the differences between the gene/protein-attributes and expression patterns between 33 KMTs/KDMs that are known/candidates for dominant DD and the other 18 KMTs/KDMs using the UniProtKB, GTEx and BrainSpan databases 50; 51; 64 .
Mann-Whitney tests were performed with an exact p-value <0.05 considered as significant.
Candidate/known dominant DD KMTs/KDMs had longer canonical transcripts, greater number of interactors and a significantly higher number and types of post-translational modifications (adjusted for protein length) ( Figure 4 ) (Tables S9 and S10) 64 . These distinctions are maintained independently for both KMTs and KDMs. This observation is consistent with general properties of genes that are considered to be haploinsufficient (HI) and adult human tissues when compared to other KDMs (Tables S12 and S14) ( Figure   4F ) 50 which agrees with previous observations regarding HI genes 27 . However, surprisingly
we did not find a significant difference between the expression of the candidate/known dominant DD KMTs versus other KMTs in most human tissues. Exceptions were certain brain-areas where the candidate/known dominant DD KMTs are significantly highly expressed before the 10 th post-conceptional week (Tables S11 and S13) ( Figure 4F ) 51 . Further studies will be needed to confirm these unexpected findings. One possibility is that the KMTs that were classified in this study as not being candidates for dominant DDs may be candidates for adult-onset phenotypes. Alternatively, these results may reflect technical limitations of large-scale gene expression experiments such as lack of cell-type level resolution.
Lastly, we turned our focus to test the hypothesis that recessive disorders associated with biallelic variants in some KMTs/KDMs may exist. This hypothesis was based on our observation that five KMT and two KDM homozygous knockout mice are viable, but show multiple anomalies (Table S1 ). In the cohort of 4,293 subjects from the DDD study, we identified 27/102 probands with bi-allelic variants in KMTs/KDMs. On subsequent analyses, most of these were considered likely non-deleterious. However, one individual had bi-allelic homozygous KDM5B (OMIM #605393) PTVs (Table S5) Variants of interest identified in this study.
Locations of selected plausible candidate variants identified in this study are shown.
Candidates genes for dominant DDs with DN PTVs are indicated in red font and the other genes are in black font. The numbers on each picture denote the corresponding individual in Table 1 
